Related Experiment Videos
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison
Barry W Wessels1, Wesley E Bolch, Lionel G Bouchet
1Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio.
Summary
Standardizing marrow dosimetry for radionuclide therapy trials is crucial. Recalculating doses using a standard blood model improved consistency, reducing uncertainties in radioimmunotherapy studies.
Area of Science:
- Nuclear medicine
- Medical physics
- Radiotherapy
Background:
- Standardizing marrow dosimetry is critical for multicenter radionuclide therapy trials.
- Intercomparison of marrow dosimetry results has become feasible in recent years.
- Radioimmunotherapy trials require accurate dose-response estimations.
Purpose of the Study:
- To analyze reported marrow dosimetry results from radioimmunotherapy trials.
- To recalculate marrow absorbed doses using a standard blood model and patient-specific data.
- To quantify and compare differences in dose estimates due to variations in methodology and assumptions.
Main Methods:
- Data from 22 patients in radiolabeled antibody trials were analyzed.
- Marrow doses were recalculated at a central facility using the AAPM/Sgouros blood model approach.
- Patient-specific source data and a standardized approach for remainder-of-body contribution were used.
Main Results:
- Recalculated marrow doses were compared to original institutional estimates.
- The mean ratio of institutional to central dose estimates was 0.920 +/- 0.259.
- Dose estimates were within 30% of centrally obtained results.
Conclusions:
- The AAPM/Sgouros method improved marrow dosimetry consistency for radiolabeled antibodies.
- Variations in methodology and assumptions still introduce uncertainty.
- A standardized method is proposed as a benchmark for intercomparison and improving dose-response correlations.